Oakworth Capital Inc. Has $85,000 Holdings in Danaher Co. (NYSE:DHR)

Oakworth Capital Inc. grew its stake in Danaher Co. (NYSE:DHR) by 24.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 367 shares of the conglomerate’s stock after buying an additional 71 shares during the period. Oakworth Capital Inc.’s holdings in Danaher were worth $85,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Drive Wealth Management LLC lifted its position in shares of Danaher by 3.1% during the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock worth $344,000 after purchasing an additional 44 shares during the last quarter. Nations Financial Group Inc. IA ADV lifted its position in shares of Danaher by 0.8% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 6,064 shares of the conglomerate’s stock worth $1,779,000 after purchasing an additional 46 shares during the last quarter. New Hampshire Trust lifted its position in shares of Danaher by 0.3% during the 3rd quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock worth $3,582,000 after purchasing an additional 50 shares during the last quarter. Connolly Sarah T. lifted its position in shares of Danaher by 0.5% during the 3rd quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock worth $2,382,000 after purchasing an additional 50 shares during the last quarter. Finally, Thrive Wealth Management LLC lifted its position in shares of Danaher by 0.9% during the 3rd quarter. Thrive Wealth Management LLC now owns 5,496 shares of the conglomerate’s stock worth $1,364,000 after purchasing an additional 51 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Royal Bank of Canada boosted their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Raymond James upped their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Barclays upped their price target on Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, April 10th. JPMorgan Chase & Co. upped their price target on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. Finally, Citigroup upped their price target on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $268.27.

Insider Buying and Selling

In related news, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total transaction of $826,032.35. Following the sale, the director now directly owns 14,129 shares in the company, valued at approximately $3,548,498.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now owns 14,129 shares in the company, valued at $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 in the last three months. Insiders own 11.10% of the company’s stock.

Danaher Trading Down 3.1 %

DHR stock opened at $232.00 on Thursday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The firm has a market cap of $171.81 billion, a P/E ratio of 37.46, a P/E/G ratio of 3.65 and a beta of 0.83. The business’s 50 day moving average is $249.28 and its 200-day moving average is $229.86. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period in the prior year, the company posted $2.87 EPS. The company’s revenue was down 10.2% compared to the same quarter last year. Equities analysts anticipate that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. Danaher’s dividend payout ratio is 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.